In the RA group 51 (47%) patients were treated with TNF-α inhibitors (adalimumab, etanercept, certolizumab, infliximab or golimumab), 15 (14%) with IL-6-inhibitor (tocilizumab), 4 (3.7%), with rituximab therapy and 5 (4.6%), and patients were treated with JAK inhibitors (baricitinib, tofacitinib; in all cases with or without DMARD/CCS, Table 2). Here, TNF is linked to rheumatoid arthritis.